Clinicopathological Variables and Outcome in Chronic Myeloid Leukemia Associated With BCR-ABL1 Transcript Type and Body Weight: An Outcome of European LeukemiaNet Project.

Objective: It is debatable whether BCR-ABL1 transcript type has an impact on outcome of treatment of patients with CML, and it is not widely studied whether body weight influences response to treatment. In this study, we tried to find out if any of these factors has an impact on response to treatmen...

Descripción completa

Detalles Bibliográficos
Publicado en:Cancer Control: Journal of the Moffitt Cancer Center Vol. 28; pp. 1 - 12
Autores principales: Abdulla, Mohammad A. J., Chandra, Prem, Akiki, Susanna El, Aldapt, Mahmood B., Sardar, Sundus, Chapra, Ammar, Nashwan, Abdulqadir J., Sorio, Claudio, Tomasello, Luisa, Boni, Christian, Yassin, Mohamed A.
Formato: Journal Article
Publicado: Sage Publications Inc. 11/18/2021
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=153654791&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 153654791
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10732748
        1CJM
      jtl: Cancer Control: Journal of the Moffitt Cancer Center
      issn: 10732748
      maglogo: Y
    pubinfo:
      dt: 11/18/2021
      vid: 28
      pid: 344
      pub: Sage Publications Inc.
      place: Thousand Oaks, California
    artinfo:
      ui:
        153654791
        153654791
        NLM34789006
        10.1177/10732748211038429
        NLM34789006
        153654791
      ppf: 1
      ppct: 11
      formats:
      tig:
        atl: Clinicopathological Variables and Outcome in Chronic Myeloid Leukemia Associated With BCR-ABL1 Transcript Type and Body Weight: An Outcome of European LeukemiaNet Project.
      aug:
        au:
          Abdulla, Mohammad A. J.
          Chandra, Prem
          Akiki, Susanna El
          Aldapt, Mahmood B.
          Sardar, Sundus
          Chapra, Ammar
          Nashwan, Abdulqadir J.
          Sorio, Claudio
          Tomasello, Luisa
          Boni, Christian
          Yassin, Mohamed A.
        affil: Department of Medical Oncology, Hematology Section, National Center for Cancer Care and Research, 36977 Hamad Medical Corporation, Doha, Qatar
      sug:
      ab: Objective: It is debatable whether BCR-ABL1 transcript type has an impact on outcome of treatment of patients with CML, and it is not widely studied whether body weight influences response to treatment. In this study, we tried to find out if any of these factors has an impact on response to treatment and outcome.Methodology: We conducted a retrospective analysis of the files of 79 patients being treated in our center for CML with known BCR-ABL1 breakpoints, and patients' management and response assessment was done based on ELN 2013 guidelines. The analysis was performed based on two main groups, obese vs. normal BMI, and then based on BCR-ABL1 transcripts: e13a2 vs. e14a2. Cumulative incidence of MMR, CCyR, and DMR were estimated using the Kaplan-Meier survival curve method, and comparisons between groups were performed by the Log-rank/Gray test methods.Results/conclusion: In the patient-cohort studied, there was no statistically significant difference in molecular response between patients with CML based on body weight or transcript type although patients in the obesity group achieved higher and faster MMR with no statistical significance.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N